<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02742233</url>
  </required_header>
  <id_info>
    <org_study_id>XinqiaoH</org_study_id>
    <nct_id>NCT02742233</nct_id>
  </id_info>
  <brief_title>Dipeptidyl Peptidase 4 Inhibition Facilitate Healing of Diabetic Ulcers</brief_title>
  <acronym>DPP4i</acronym>
  <official_title>A Controlled Clinical Trial of Dipeptidyl Peptidase 4 Inhibition Facilitate Healing of Diabetic Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Long Min,MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xinqiao Hospital of Chongqing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effect of Dipeptidyl Peptidase 4 Inhibition on wound healing in patients
      with diabetic foot ulcers, the investigators randomly divided the participants into two
      groups: saxagliptin with regular treatment group，placebo with regular treatment group. The
      clinical data are collected at the given time point. This study aimed to observe the
      potential protective effect of DPP4i on diabetic ulcers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Groups:

      Diabetic ulcers, saxagliptin + Regular treatment.

      Diabetic ulcers, placebo + Regular treatment.

      Time Point:

      Initial treatment;

      Post-treatment ( 1w );

      Post-treatment ( 2w );

      Post-treatment ( 4w );

      Completely healed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Completely healing time of the participants'target ulcer during the treatment period.</measure>
    <time_frame>16 weeks</time_frame>
    <description>Complete ulcer closure is defined as 100% skin re-epithelialization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with complete healing during the treatment period.</measure>
    <time_frame>16 weeks</time_frame>
    <description>Complete ulcer closure is defined as 100% skin re-epithelialization</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Net change from baseline in laboratory test results</measure>
    <time_frame>Baseline, weeks 1, 2,4,</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>New ulcers</measure>
    <time_frame>16 weeks</time_frame>
    <description>new ulcers among the participants during treatment period</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>saxagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>saxagliptin &amp; Regular treatment:
saxagliptin, brand name，Bristol-Myers, Squibb, dose: 5mg, po, qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo &amp; Regular treatment:
placebo, dose: 5mg, po, qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saxagliptin</intervention_name>
    <description>Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.
Treatment Period: Participants will receive saxagliptin with regular treatment</description>
    <arm_group_label>saxagliptin</arm_group_label>
    <other_name>ONGLYZA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.
Treatment Period: Participants will receive placebo with regular treatment</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>dummy pills</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of diabetes mellitus according to World Health Organization criteria (
             treatment with insulin or an oral hypoglycemic agent, twice random glucose
             measurements major than 200 mg/dl, or a fasting glucose major than 140 mg/dl)

          -  Ulcer located on the legs or feet, stage III or IV (Wagner Classification System)

          -  The subject agrees to comply with study protocol requirements and all follow up visit
             requirements.

        Exclusion Criteria:

          -  Uncontrolled diabetes

          -  Ulcer infection

          -  Non-diabetic ulcers Orthopedic or neuromuscular pathologic conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongting Zheng, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Endocrinology,The Second Affiliated Hospital, Third Military Medical University, Chongqing, People's Republic of China.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Long, MD</last_name>
    <phone>023-68763255</phone>
    <email>longmin_casper@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leiqin Cai</last_name>
    <phone>18580027792</phone>
    <email>caileiqin@outlook.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Second Affiliated Hospital, Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hongting Zheng, Ph.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2016</study_first_submitted>
  <study_first_submitted_qc>April 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2016</study_first_posted>
  <last_update_submitted>August 6, 2017</last_update_submitted>
  <last_update_submitted_qc>August 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Xinqiao Hospital of Chongqing</investigator_affiliation>
    <investigator_full_name>Long Min,MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Wound Healing</keyword>
  <keyword>Dipeptidyl Peptidase 4 Inhibition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saxagliptin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>age，the grade of the diabetic ulcers, sex, diabetes duration, healing time, treatment. ect</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>December 25, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

